Neil S. Belloff
General Counsel bij ACORDA THERAPEUTICS, INC.
Vermogen: - $ op 31-03-2024
Profiel
Neil S.
Belloff is currently the Secretary & General Counsel at Acorda Therapeutics, Inc. He previously worked as the Senior Corporate Counsel at Celgene Corp.
and as the Executive VP, US Corporate & Securities Counsel at Deutsche Telekom AG.
From 2020 to 2021, he served as the COO, Secretary, EVP & General Counsel at Eloxx Pharmaceuticals, Inc. Mr. Belloff completed his undergraduate studies at Queens College and his graduate studies at New York University.
He also obtained a graduate degree from Quinnipiac University School of Law.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 24-04-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Neil S. Belloff
| Bedrijven | Functie | Begin |
|---|---|---|
| ACORDA THERAPEUTICS, INC. | General Counsel | 08-11-2021 |
Eerdere bekende functies van Neil S. Belloff
| Bedrijven | Functie | Einde |
|---|---|---|
| ELOXX PHARMACEUTICALS, INC. | Chief Operating Officer | 25-08-2021 |
| CELGENE | Corporate Officer/Principal | - |
| DEUTSCHE TELEKOM AG | Corporate Officer/Principal | - |
Opleiding van Neil S. Belloff
| Queens College | Undergraduate Degree |
| New York University | Graduate Degree |
| Quinnipiac University School of Law | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| DEUTSCHE TELEKOM AG | Communications |
| ACORDA THERAPEUTICS, INC. | Health Technology |
| ELOXX PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
